Pharvaris NV, a clinical-stage biotechnology company based in Leiden, Netherlands, is making strides in the health care sector with its focus on the discovery and development of novel oral B2 receptor antagonists. The company, which operates primarily in the Netherlands and Switzerland, is listed on the Frankfurt Stock Exchange and trades in euros (EUR).
As of the close of trading on March 9, 2026, Pharvaris NV’s share price stood at €21.80. Over the past year, the company’s stock has experienced significant volatility, with a 52-week high of €25.20 on December 2, 2025, and a 52-week low of €10.20 on April 13, 2025. This fluctuation reflects the inherent risks and potential rewards associated with clinical-stage biotech firms.
Pharvaris NV’s market capitalization is currently valued at approximately €1.44 billion. Despite its promising pipeline, the company’s financial metrics reveal some challenges. The price-to-earnings (P/E) ratio is reported at -8.023, indicating that the company is not currently generating positive earnings. This negative P/E ratio is not uncommon for companies in the biotech sector, particularly those in the clinical development phase, as they often prioritize research and development over immediate profitability.
The price-to-book (P/B) ratio of 4.63 suggests that the market values Pharvaris NV at about four and a half times its book equity. This valuation reflects investor confidence in the company’s long-term potential, despite its current lack of profitability.
In its latest corporate update on January 12, 2026, Pharvaris NV outlined its strategic priorities for the year. The company emphasized its commitment to advancing its pipeline of B2 receptor antagonists, which hold promise for treating various conditions. However, the update did not introduce any new market catalysts, leaving investors to focus on the company’s ongoing clinical trials and research efforts.
Pharvaris NV continues to operate with a clear focus on innovation and patient care, aiming to bring new therapeutic options to market. As the company progresses through its clinical trials, stakeholders will be closely monitoring its developments and potential breakthroughs in the treatment landscape.
